Understanding AMH Levels in Healthy Girls
Official title: Anti-mullerian Hormone Levels in Healthy Females
Run by Ann & Robert H Lurie Children's Hospital of Chicago · NCT04537390 · Data updated 2026-11-12
This study is trying to find out the normal levels of a hormone called AMH in girls aged 0-18 to help understand their reproductive health and fertility options, especially for young cancer patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 18 Years |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | July 19, 2016 |
| Main results expected | December 1, 2030 |
| Study ends | December 1, 2030 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT04537390 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pre- and post-pubertal females aged 0-18 years who are undergoing routine outpatient surgical procedures.
✕Probably not a fit
Patients with a history of conditions associated with premature ovarian failure or those who have undergone cancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to investigate the normal blood levels of anti-mullerian hormone (AMH) in females aged 0-18 years and how these levels relate to their reproductive development. By collecting blood samples from pre- and post-pubertal females undergoing routine outpatient surgical procedures, researchers hope to establish a baseline for AMH levels in this population. This understanding could help assess the risk of infertility in young cancer patients and provide options for preserving fertility. The study focuses on a specific age group and aims to fill the knowledge gap regarding AMH levels in children and adolescents.
Why it matters
Potential benefit: If successful, this study could improve fertility preservation strategies for young females at risk of infertility due to cancer treatments.
How similar studies have gone: While studies on AMH levels in adults have shown success, this specific focus on children and adolescents is relatively novel and less explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pre- and post-pubertal females 2. Ages 0-18 years old 3. Tanner Stage I- V 4. Undergoing routine outpatient surgical procedure 1. Hernia repair (inguinal, umbilical, epigastric) 2. Excision of benign mass 3. laparoscopic cholecystectomy Exclusion Criteria: 1. Previous diagnosis of an illness associated with premature ovarian failure (Turner's syndrome, Fragile X permutation carrier) or endocrine disorder associated with irregular menstrual cycles (Cushing's disease, poorly-controlled Thyroid disease, hyperprolactinemia, polycystic ovary syndrome, and congenital adrenal hyperplasia) or insulin-dependent diabetes mellitus or autoimmune disorders 2. Previous diagnosis of any malignancy or any history of systemic/local chemotherapy, radiation therapy, or stem-cell transplant. 3. Previous surgical excision of one ovary or both ovaries 4. Pregnant females 5. All inpatient surgical patients 6. Undergoing non-routine outpatient surgical procedures 1. Central venous catheter placement 2. Supprelin insertion/removal 3. Breast mass excision 4. Gastrostomy tube insertion
Where it's running
-
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Erin Rowell, MD — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Jacquelyn Searcy
- Email: FertilityPreservationMB@luriechildrens.org
- Phone: 3122274758
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.